Dr Enrique Ocio talks to ecancer about the update of safety and efficacy of isatuximab short-duration fixed-volume infusion plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT.
He begins by talking about the methodology explaining that the study was split into 2 parts. Part A, a weight-based infusion of IsaVRd was effective and well tolerated (median infusion duration at first infusion, 3.7 hours). Part B, where Isa (10 mg/kg) was administered as a fixed-volume infusion of 250 mL with standard doses of VRd. The primary endpoint is the complete response rate of Isa-VRd.
Dr Ocio then talks about the findings and how the median duration of Isa infusion decreased to 1.3 hours from the third infusion onward.
The overall response rate was 97.8%, including a CR/stringent CR (sCR) rate of 35.6% and very good partial response rate of 55.6%.
He concludes that results confirm the feasibility, efficacy, and safety of the approved short-duration fixed-volume infusion method of Isa in combination with VRd in patients with NDMM ineligible/with no immediate intent for ASCT.
Isa-VRd is under investigation in ongoing Phase 3 studies.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.